论文部分内容阅读
Functional Diagnostics for Cancer Precision Medicine using Patient-Derived Cell Models
【机 构】
：
Department of Pathology,Center for Cell Reprogramming,Georgetown University Medical Center,Washingto
【出 处】
：
2016医学科学前沿暨第四届个体化治疗与抗肿瘤药物研究新趋向研讨会
【发表日期】
：
2016年10期
其他文献
Treatment of osimertinib(AZD9291)-resistant non-small cell lung cancer HCC-827/OSIR cells by targeti
Objective: The third generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)osimertinib(OSI,also known as AZD9291)has been approved for treatment of EGFR T790M positive mutatio
Targeting tumor hypoxia of HCC by a novel drug candidate CT-707 through disruption of hypoxia-activa
Purpose: Intratumor hypoxia is a hallmark of hepatocellular carcinoma cells(HCC),leading to therapeutic resistance and malignant progression.Various strategies have been developed to combat with the h
Objective: The mTOR inhibitors have been demonstrated clinical benefits in many cancers(kidney,breast cancer,etc),while the efficacy of mTOR inhibitors in non-small cell lung cancer(NSCLC)remains unce
Osthole inhibited epithelial-mesenchymal transition(EMT)by suppressing NF-κB mediated Snail activati
Objective: Osthole(OST),an active constituent of Chinese herb Cnidium monnieri,has been reported to inhibit cancer metastasis while the mechanisms remains unclear.Here,we studied the inhibitory effect
Objective: Heat shock protein 90(Hsp90)is a therapeutic target for cancer treatment,and inhibition of Hsp90 will presumably result in suppression of multiple survival signaling pathways.Platycodin D(P
Objective: 2-Methoxy-6-acetyl-7-methyljuglone(MAM)is an active naphthoquinone component of Polygonum cuspidatum used as Chinese herb medicine for treatment of inflammation,hyperlipidemia and cancer.Th
Objective: Doxorubicin is a widely used antineoplastic agent in clinics for treating a wide range of cancers.However,the clinical use is largely limited by its cardiotoxicity of the heart.DS-36 is a n
Hepatocellular carcinoma(HCC)is the sixth most frequent malignant tumor with poor prognosis,and its clinical therapeutic outcome is poor.Volasertib,a potent small molecular inhibitor of polo-like kina
会议